Definitive Healthcare Corp. (NASDAQ:DH) Not Doing Enough For Some Investors As Its Shares Slump 26%
Definitive Healthcare Corp. (NASDAQ:DH) has seen its shares drop significantly, with a 26% decline in the last month and a 65% drop over the past year. Its low price-to-sales (P/S) ratio of 0.8x, compared to an industry average of 2.1x, reflects declining revenues and a negative growth outlook. Analysts forecast a 3.0% revenue decrease for the company while the industry is expected to grow by 12%, justifying the current low valuation but signaling potential difficulties for share price recovery.
Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Rating of "Hold" from Brokerages
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $3.94. The company recently beat its earnings and revenue estimates but still posted a negative net margin of 77.88%. Institutional investors hold approximately 98.67% of the company's stock, which currently trades around $2.32.
Definitive Healthcare Corp. to Announce Q4 and Full Year 2025 Financial Results on February 26, 2026
Definitive Healthcare Corp. (Nasdaq: DH) plans to announce its financial results for the fourth quarter and full year ended December 31, 2025, on February 26, 2026, after market close. The company will host a conference call and webcast at 5:00 PM ET to discuss the results, with replay options available until March 26, 2026. This announcement highlights their commitment to transparency and investor engagement, detailing recent hedge fund activity and analyst ratings, including a "Buy" rating from Stifel.
Definitive Healthcare Corp. to Announce Q4 and Full Year 2025 Financial Results on February 26, 2026
Definitive Healthcare Corp. (Nasdaq: DH) plans to release its financial results for the fourth quarter and full fiscal year ending December 31, 2025, on February 26, 2026, after the market closes. Following the announcement, the company will host a conference call and webcast at 5:00 PM ET to discuss the results and engage with investors. The article also provides details on Definitive Healthcare's recent financial performance, hedge fund activity, analyst ratings, and price targets.
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN) and Definitive Healthcare Corp (DH)
Analysts have issued neutral ratings for AMN Healthcare Services (AMN) and Definitive Healthcare Corp (DH), indicating neither bullish nor bearish sentiment. Needham analyst Ryan MacDonald maintained a Hold rating on Definitive Healthcare Corp, whose shares closed at $2.43. The consensus price target for Definitive Healthcare Corp is $3.71.
Short Interest in Definitive Healthcare Corp. (NASDAQ:DH) Drops By 23.2%
Definitive Healthcare Corp. (NASDAQ:DH) experienced a 23.2% drop in short interest in December, reaching 2,248,253 shares, representing 1.9% of its shares sold short and a short-interest ratio of 2.9 days. Analysts generally have a "Hold" rating with an average target price of $3.94, despite recent downgrades and lower price targets from several firms. The company's stock currently trades at $2.39, with a market capitalization of approximately $338 million, after reporting mixed financial results including beating quarterly EPS estimates but having a deeply negative net margin.
Definitive Healthcare Corp. Reports Q3 2025 Results
This article reports on Definitive Healthcare Corp.'s third-quarter 2025 financial results. It details the company's performance during this period.
Definitive Healthcare Corp. (NASDAQ:DH) Receives Consensus Recommendation of "Hold" from Analysts
Nine analysts currently give Definitive Healthcare Corp. (NASDAQ:DH) a consensus "Hold" rating, with an average 12-month price target of $3.94, compared to its recent share price of around $2.56. The company recently exceeded EPS and revenue estimates but continues to report a negative net margin. Institutional investors hold a significant majority (98.67%) of the stock.
Definitive Healthcare greatly expands all-payor medical and prescription claims coverage
Definitive Healthcare announced a significant expansion of its prescription and all-payor medical claims data within the Atlas Dataset, increasing coverage by over 60% for prescription claims and considerably for all-payor claims, including a nearly 20% rise in key areas like rare disease and oncology. This expansion, coupled with refined methodologies and increased patient overlap, provides clients with a more in-depth and holistic view of patient journeys to better understand market trends, inform product development, and optimize go-to-market strategies. The enhanced data aims to accelerate commercial success for organizations partnering with healthcare providers.
Definitive Healthcare to Present at the 28th Annual Needham Growth Conference
Definitive Healthcare (Nasdaq: DH) announced that its CFO, Casey Heller, will present at the 28th Annual Needham Growth Conference on January 14, 2026, at 9:30 a.m. Eastern Time. A live webcast of the presentation will be available on the company's investor relations website, with a replay also accessible for a limited duration. Definitive Healthcare provides healthcare market data and analytics to help organizations make strategic decisions.
Definitive Healthcare (NASDAQ:DH) Cut to Buy at Wall Street Zen
Wall Street Zen downgraded Definitive Healthcare (NASDAQ:DH) from "strong-buy" to "buy" on Sunday, contributing to a mixed analyst consensus rating of "Hold" and a $3.94 price target for the stock. Despite this, the company exceeded Q3 EPS estimates and provided positive FY2025 guidance. Institutional investors hold a significant 98.7% of the shares, while the stock currently trades at $2.63 with a negative P/E ratio.
Definitive Healthcare (NASDAQ:DH) Upgraded by Wall Street Zen to Strong-Buy Rating
Definitive Healthcare (NASDAQ:DH) has been upgraded from a "buy" to a "strong-buy" rating by Wall Street Zen. The company slightly beat its last quarter's EPS and revenue estimates, and analysts currently have a consensus "Hold" rating with an average price target of $3.94. Several institutional investors have recently acquired positions in DH.
Definitive Healthcare price target lowered to $3.50 from $5 at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach has lowered the price target for Definitive Healthcare (DH) to $3.50 from $5, maintaining an Equal Weight rating. The analyst sees an attractive backdrop for alpha-generation opportunities in healthcare technology and providers for 2026. This adjustment comes amidst expectations of continued policy, reimbursement, and utilization headwinds for managed care stocks in 2025.
Definitive Healthcare price target lowered to $2.75 from $3 at Barclays
Barclays has lowered its price target for Definitive Healthcare to $2.75, down from the previous $3.00. The firm maintains an "Equalweight" rating on the stock.
Definitive Healthcare Corp. (NASDAQ:DH) Given Average Rating of "Hold" by Brokerages
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Hold" rating from nine brokerages, with an average 12-month price target of $4.19. The company has a negative P/E ratio, trading below its moving averages, but recently beat quarterly EPS and revenue estimates. Institutional investors have made significant changes to their positions, with 98.67% of the stock owned by institutions.
Barclays Maintains Definitive Healthcare (DH) Underweight Recommendation
Barclays has maintained an "Underweight" recommendation for Definitive Healthcare (NasdaqGS:DH). Despite this, analysts forecast a 68.85% upside with an average one-year price target of $4.14/share. Institutional ownership shows significant holdings by Advent International and Goldman Sachs Group, though some firms have decreased their allocations.
Definitive Healthcare price target lowered to $2.75 from $3 at Barclays
Barclays has lowered its price target for Definitive Healthcare (DH) from $3 to $2.75, while maintaining an Equal Weight rating on the shares. This adjustment follows a transfer of coverage and reflects a neutral view on the U.S. healthcare technology and distribution industry. The firm is most optimistic about drug distributors but has a more mixed outlook for dental and healthcare information technology sectors.
Definitive Healthcare Corp. Forms Death Cross, Signaling Bearish Trend Ahead
Definitive Healthcare Corp. has experienced a Death Cross, a technical indicator suggesting a bearish trend, as its short-term moving average fell below its long-term moving average. The company's technical indicators, including MACD and Bollinger Bands, confirm a downward outlook. This event follows a significant decline in its stock performance over the past year, contrasting sharply with the S&P 500's gains.
Definitive Healthcare Q3 2025 slides: Revenue decline continues despite earnings beat By Investing.com
Definitive Healthcare (NASDAQ: DH) reported a 4% year-over-year revenue decline in Q3 2025, reaching $60 million, but exceeded analyst expectations with adjusted EPS of $0.07. Despite beating profitability estimates, the stock fell 2.57%, reflecting ongoing investor caution due to macroeconomic headwinds and a continued revenue growth challenge. The company projects a further 4-5% revenue decline for Q4 2025 but raised its full-year adjusted EBITDA guidance, while focusing on strategic initiatives to return to growth in 2026.
Definitive Healthcare Q3 2025 slides: Revenue decline continues despite earnings beat
Definitive Healthcare (NASDAQ:DH) reported Q3 2025 earnings, exceeding analyst expectations for EPS at $0.07 despite a 4% year-over-year revenue decline to $60 million. The company's stock fell 2.57% following the announcement, reflecting investor concerns over its growth trajectory amidst macroeconomic headwinds. Definitive Healthcare offered cautious guidance for Q4 2025 and reaffirmed its full-year outlook, emphasizing profitability and strategic initiatives for future growth.
Definitive Healthcare (Nasdaq: DH) sets results call for Nov. 6 at 5 PM ET
Definitive Healthcare (Nasdaq: DH) announced it will report its third-quarter 2025 financial results on Thursday, November 6, 2025, after market close. The company will also host a conference call and webcast at 5:00 PM ET/2:00 PM PT on the same day to discuss the results. Investors can access the webcast and dial-in details via the company's investor relations website.
Definitive Healthcare (NASDAQ: DH) sets fourth-quarter revenue view at $59M–$60M
Definitive Healthcare reported strong Q3 2025 results, meeting or exceeding guidance with $60.0M revenue and Adjusted EBITDA of $18.9M. The company also provided Q4 2025 revenue guidance of $59.0M–$60.0M and raised its full-year 2025 revenue forecast to $239.0M–$240.0M, highlighting improvements in new-logo acquisitions and customer retention. Despite a 4% year-over-year revenue decrease, the company demonstrated operational profitability and positive cash flow.
Definitive Healthcare Earnings Call: Mixed Sentiment Amid Challenges
Definitive Healthcare's recent Q3 earnings call revealed mixed sentiment, showcasing strong profitability and cash flow, alongside growth in enterprise customers and improved retention rates. However, the company also reported a 4% year-over-year revenue decline and continued pressure in the life sciences segment. Despite strategic partnerships and operational efficiencies, macroeconomic uncertainties temper the overall outlook.
Definitive Healthcare : DH Earnings Presentation Q3 2025 v2
Definitive Healthcare (DH) reported its Q3 2025 earnings, showcasing continued progress in strategic areas, particularly in new logo production and retention rates. The company delivered results at or above the high end of its guidance for both top and bottom lines, despite a dynamic environment. Definitive Healthcare also updated its full-year 2025 guidance, raising the midpoint for both revenue and non-GAAP profit, reflecting solid Q3 performance and a positive Q4 outlook.
Definitive Healthcare (NASDAQ:DH) Receives Sell (D-) Rating from Weiss Ratings
Definitive Healthcare (NASDAQ:DH) received a "Sell (D-)" rating from Weiss Ratings. Despite this negative outlook, Stifel Nicolaus upgraded its price target for DH to $6.00 with a "buy" rating. The stock is currently trading at $2.97, with a consensus "Reduce" rating and an average price target of $4.28 from analysts.
Definitive Healthcare Corp. (NASDAQ:DH) Receives Consensus Recommendation of "Reduce" from Analysts
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Reduce" recommendation from analysts, with an average 1-year price target of $4.28. Institutional investors hold a significant 98.67% of the company's stock, indicating strong interest. The article details recent analyst ratings and institutional trading activity, along with the company's price performance and profile.
Definitive Healthcare to Report Third Quarter Financial Results on November 6, 2025
Definitive Healthcare Corp. announced it will release its Q3 2025 financial results on November 6, 2025, after market close, followed by a conference call and webcast at 5:00 PM ET. The company will provide data on its performance in healthcare commercial intelligence, and a replay of the call will be available until December 6, 2025. This allows for transparency and engagement with investors, highlighting its position as an industry leader.
Forum Ventures Bets Big on Category-Defining Vertical AI Solution for Healthcare Growth, Salubrum
Salubrum, a vertical AI company, has launched an AI-first commercialization engine for healthcare growth, aiming to productize and automate traditional marketing agencies in the sector. Backed by Forum Ventures and partnered with Definitive Healthcare (NASDAQ: DH), Salubrum is disrupting legacy models by providing precision patient activation and 1:1 programmatic advertising to help healthcare brands connect with high-intent patients. The startup, founded by Osama Usmani, has achieved $60,000 USD in ARR and a $2M USD valuation by offering a specialized AI solution trained on healthcare-specific data and KPIs.
Definitive Healthcare at Morgan Stanley Conference: Strategic Turnaround Insights
Definitive Healthcare presented its strategic vision at the Morgan Stanley 23rd Annual Global Healthcare Conference, focusing on stabilizing revenue, returning to growth, and leveraging AI. CEO Kevin Coop and CFO Casey Heller outlined four strategic pillars: data quality, integrations, customer success, and innovation. The company aims to enhance data manipulation and customer retention despite macroeconomic challenges, particularly in the life sciences sector.
Definitive Healthcare Q2 2025 slides: revenue decline continues but exceeds guidance
Definitive Healthcare (NASDAQ: DH) reported Q2 2025 financial results, showing a 5% year-over-year revenue decline but exceeding company guidance. The healthcare data analytics provider maintained strong profitability with a 31% adjusted EBITDA margin and raised its full-year 2025 guidance, indicating management's confidence despite ongoing revenue challenges. The company also improved its balance sheet by reducing total debt and continues its share buyback program.
Definitive Healthcare Q1 2025 slides: revenue declines 7% YoY, beats guidance
Definitive Healthcare (NASDAQ: DH) reported Q1 2025 revenue of $59.2 million, a 7% year-over-year decline but exceeding guidance. Despite margin compression and a significant goodwill impairment charge, the company showed strong cash flow and reduced debt. Management raised full-year 2025 revenue guidance, indicating stabilization despite ongoing market headwinds and investor skepticism.
DH Stock Price and Chart — NASDAQ:DH
This article provides a comprehensive overview of Definitive Healthcare Corp. (NASDAQ: DH) stock, including its current price, historical performance, key financial statistics, and analyst ratings. It details the company's business activities, upcoming earnings, and mentions its inclusion in various ETFs, offering potential investors a complete snapshot of its market position.
Definitive Healthcare Shares Tumble On Weak Q4 Results, 2025 Outlook
Definitive Healthcare Corp. (DH) saw its shares drop significantly after reporting weak Q4 2024 financial results and a disappointing 2025 outlook. The company's revenue declined, and its net loss widened due to goodwill impairment charges. Definitive Healthcare also announced the appointment of Casey Heller as its new Chief Financial Officer.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Definitive Healthcare Corp. (DH) on Behalf of Investors
Glancy Prongay & Murray LLP has launched an investigation into Definitive Healthcare Corp. (NASDAQ: DH) on behalf of investors concerning alleged violations of federal securities laws. This investigation follows a significant drop in Definitive Healthcare's stock price by 32.1% on July 31, 2024, after the company disclosed a $363.6 million goodwill impairment and reduced its fiscal year 2024 guidance. The law firm is encouraging investors who suffered losses to contact them to explore potential claims.
Richard Booth to Leave Definitive Healthcare Corp. as Chief Financial Officer, Effective June 1, 2025
Definitive Healthcare Corp. announced that its Chief Financial Officer, Richard Booth, will be leaving the company effective June 1, 2025, following discussions regarding the scope of his role. Booth will continue in his position until this date, or until a successor is appointed. His departure is considered a termination without "cause" for employment and benefit agreements.
Definitive Healthcare Appoints Kevin Coop as CEO
Definitive Healthcare Corp. (Nasdaq: DH) has appointed Kevin Coop as its new Chief Executive Officer and a member of the Board of Directors, effective June 24, 2024. Coop succeeds founder Jason Krantz, who will remain Executive Chairman. Coop brings over 30 years of experience in data and analytics-focused businesses, previously serving as CEO of DailyPay, Inc. and holding leadership roles at Dun & Bradstreet and Black Knight.
Earnings call: Definitive Healthcare reports mixed Q1 2024 results By Investing.com
Definitive Healthcare (NASDAQ: DH) reported mixed Q1 2024 results, meeting revenue expectations with $63.5 million (7% year-over-year increase) but underperforming in new logo and upsell expectations due to macroeconomic headwinds and internal restructuring. The company announced a $20 million share buyback program and adjusted its full-year guidance downwards. Despite challenges, Definitive Healthcare saw improved customer renewal rates, particularly among enterprise clients, and is focused on operational efficiencies and product innovation, including the integration of recent acquisitions like Carevoyance and the expansion of its claims analytics platform.
Definitive Healthcare CEO steps down after two years at helm
Robert Musslewhite has stepped down as CEO of Definitive Healthcare after two years, with founder Jason Krantz taking over as interim CEO. This change follows previous layoffs and acquisitions by the company.
Definitive Healthcare Corp. Announces Executive Changes, Effective November 1, 2023
Definitive Healthcare Corp. announced the appointment of Carrie Lazorchak as Chief Revenue Officer, effective November 1, 2023. Lazorchak previously served as Chief Revenue Officer at SimilarWeb and held various sales leadership roles at Nuance Communications. Joe Mirisola, the current Chief Revenue Officer, will transition to a Senior Advisor role before leaving the company at the end of 2023.
Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2022
Definitive Healthcare Corp. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2022, reporting significant revenue growth of 31% for Q4 and 34% for the full year. The company highlighted key customer wins and the introduction of its "Atlas Dataset" for healthcare commercial intelligence. Definitive Healthcare also provided financial guidance for the first quarter and full year 2023, projecting continued revenue growth.
Definitive Healthcare: A High Growth Company On Sale (NASDAQ:DH)
Definitive Healthcare's stock has dropped significantly since its 2021 IPO, making it an attractive investment opportunity. The company, operating in a large and growing healthcare technology market, exhibits impressive growth and strong profitability despite macro headwinds. Its current valuation is considered appealing compared to other high-growth SaaS companies, leading to a "buy" rating.
Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Year Fiscal 2021
Definitive Healthcare (Nasdaq: DH) announced strong financial results for Q4 and the full year 2021, with revenue increasing by 38% and 40% respectively, driven by growth in its enterprise client base and strategic innovations like the Latitude Reporting product and the acquisition of Analytical Wizards. The company also provided optimistic financial guidance for the first quarter and full year 2022, expecting continued revenue growth and increased profitability.
Los Angeles Daily News - Definitive Healthcare Announces Closing of Public Offering
Definitive Healthcare Corp. announced the closing of its initial public offering of 17,888,888 shares of its Class A common stock, including the full exercise of the underwriters' option. The offering was priced at $27.00 per share, generating approximately $483 million in gross proceeds before expenses. The company's Class A common stock began trading on Nasdaq under the ticker symbol "DH" on September 15, 2021.
Definitive Healthcare Prices IPO At $27/Shr
Definitive Healthcare Corp. is making its Nasdaq Global Market debut under the ticker symbol "DH" after pricing its IPO at $27 per share for 15.56 million shares of Class A common stock. The Framingham, Massachusetts-based company, a provider of healthcare commercial intelligence through a SaaS platform, reported a net loss of $25.5 million and revenue of $76.8 million for the first half of 2021. The offering is expected to close on September 17, 2021, with underwriters having a 30-day option for an additional 2.33 million shares.
